Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRuE-CHE2: Ruxolitinib in Chronic Hand Eczema
NCT05233410Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in chronic hand eczema (CHE) comparing Ruxolitinib with Vehicle (2 arms). Primary endpoint: Investigator's Global Assessment-Chronic Hand Eczema Treatment Success at 16 weeks. Planned start Jan 2023; status: withdrawn.
02
Drugs
ruxolitinib cream
03
Conditions
chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT05233410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233410.